Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Cara Chandler Wilson

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-4601

    Collapse Research 
    Collapse research activities and funding
    K08AI001459     (WILSON, CARA C)Apr 1, 1997 - Mar 31, 2002
    NIH/NIAID
    DENDRITIC CELL DEPENDENT IMMUNITY TO HIV1
    Role: Principal Investigator

    R21AI042704     (WILSON, CARA C)Sep 30, 1997 - Sep 29, 2000
    NIH/NIAID
    DENDRITIC CELL HIV VACCINES IN HLA TRANSGENIC MICE
    Role: Principal Investigator

    R21AI054192     (WILSON, CARA C)Feb 15, 2003 - Jan 31, 2006
    NIH/NIAID
    Interactions Between Recombinant Yeast and Blood DCs
    Role: Principal Investigator

    R01AI065275     (WILSON, CARA C)Jun 15, 2006 - May 31, 2011
    NIH/NIAID
    HIV-related blood dendritic cell dysfunction
    Role: Principal Investigator

    K24AI074343     (WILSON, CARA C)Dec 15, 2007 - Nov 30, 2012
    NIH/NIAID
    Interface of Innate and Adaptive Immunity in HIV-1 Infection
    Role: Principal Investigator

    R01DK088663     (WILSON, CARA C)Sep 20, 2010 - Jun 30, 2014
    NIH/NIDDK
    Mechanisms of HIV-associated Disruption of Intestinal Homeostasis
    Role: Principal Investigator

    R01AI108404     (WILSON, CARA C.)May 15, 2013 - Apr 30, 2018
    NIH/NIAID
    Mechanisms of HIV-associated Gut T Cell Depletion
    Role: Principal Investigator

    R56AI116271     (SANTIAGO, MARIO LUIS)Apr 16, 2015 - Mar 31, 2016
    NIH/NIAID
    HIV-Associated Interferon Effector Mechanisms in the GALT
    Role: Co-Principal Investigator

    R56AI118983     (BARKER, EDWARD)Jun 15, 2015 - May 31, 2016
    NIH/NIAID
    Switch from homeostatic to inflammatory cytokines by NK/ILC in HIV-infected gut
    Role: Co-Principal Investigator

    R01AI118983     (BARKER, EDWARD)Aug 15, 2015 - Feb 29, 2020
    NIH/NIAID
    Switch from homeostatic to inflammatory cytokines by NK/ILC in HIV-infected gut
    Role: Co-Principal Investigator

    R01AI134220     (SANTIAGO, MARIO LUIS)May 1, 2017 - Apr 30, 2022
    NIH/NIAID
    Role of Type I IFNs in Mucosal HIV-1 Immunity and Pathogenesis
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dillon SM, Castleman MJ, Frank DN, Austin GL, Gianella S, Cogswell AC, Landay AL, Barker E, Wilson CC. Inflammatory colonic innate lymphoid cells are increased during untreated hiv-1 infection and associated with markers of gut dysbiosis and mucosal immune activation. J Acquir Immune Defic Syndr. 2017 Aug 18. PMID: 28825942.
      View in: PubMed
    2. Yoder AC, Guo K, Dillon SM, Phang T, Lee EJ, Harper MS, Helm K, Kappes JC, Ochsenbauer C, McCarter MD, Wilson CC, Santiago ML. The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria. PLoS Pathog. 2017 Feb; 13(2):e1006226. PMID: 28241075.
      View in: PubMed
    3. Liu J, Williams B, Frank D, Dillon SM, Wilson CC, Landay AL. Inside Out: HIV, the Gut Microbiome, and the Mucosal Immune System. J Immunol. 2017 Jan 15; 198(2):605-614. PMID: 28069756.
      View in: PubMed
    4. Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS. 2016 Nov 28; 30(18):2737-2751. PMID: 27755100.
      View in: PubMed
    5. Lavender KJ, Gibbert K, Peterson KE, Van Dis E, Francois S, Woods T, Messer RJ, Gawanbacht A, Müller JA, Münch J, Phillips K, Race B, Harper MS, Guo K, Lee EJ, Trilling M, Hengel H, Piehler J, Verheyen J, Wilson CC, Santiago ML, Hasenkrug KJ, Dittmer U. Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo. J Virol. 2016 Jul 01; 90(13):6001-13. PMID: 27099312; PMCID: PMC4907223 [Available on 12/10/16].
    6. Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, Clifford D, Douek D, Silvestri G, Landay AL, Lederman MM. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Res Hum Retroviruses. 2016 Jul; 32(7):636-47. PMID: 26935044; PMCID: PMC4931767 [Available on 07/01/17].
    7. Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):163-71. PMID: 26761518; PMCID: PMC4712745 [Available on 02/01/17].
    8. Dillon SM, Lee EJ, Donovan AM, Guo K, Harper MS, Frank DN, McCarter MD, Santiago ML, Wilson CC. Enhancement of HIV-1 infection and intestinal CD4+ T cell depletion ex vivo by gut microbes altered during chronic HIV-1 infection. Retrovirology. 2016 Jan 14; 13:5. PMID: 26762145; PMCID: PMC4712466.
    9. Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, Hasenkrug KJ, Dittmer U, Wilson CC, Santiago ML. Interferon-a Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog. 2015; 11(11):e1005254. PMID: 26529416; PMCID: PMC4631339.
    10. Erlandson KM, Allshouse AA, Rapaport E, Palmer BE, Wilson CC, Weinberg A, MaWhinney S, Campbell TB. Physical function impairment of older, HIV-infected adults is associated with cytomegalovirus immunoglobulin response. AIDS Res Hum Retroviruses. 2015 Sep; 31(9):905-12. PMID: 26061347; PMCID: PMC4553372.
    11. Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, Wilson CC. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015 Mar 01; 211(5):780-90. PMID: 25214516; PMCID: PMC4334803.
    12. Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15; 210(10):1549-54. PMID: 24864123; PMCID: PMC4215074.
    13. Steele AK, Lee EJ, Vestal B, Hecht D, Dong Z, Rapaport E, Koeppe J, Campbell TB, Wilson CC. Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signature. PLoS One. 2014; 9(5):e97171. PMID: 24819230; PMCID: PMC4018269.
    14. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15; 210(8):1248-59. PMID: 24795473; PMCID: PMC4192039.
    15. Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Read SW, Janik J, Meres DS, Lederman MM, Mong-Kryspin L, Shaw KE, Zimmerman LG, Leavitt R, De La Rosa G, Jennings A. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 2014; 9(3):e90485. PMID: 24603872; PMCID: PMC3946168.
    16. Dillon SM, Lee EJ, Bramante JM, Barker E, Wilson CC. The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression. J Acquir Immune Defic Syndr. 2014 Mar 01; 65(3):259-67. PMID: 24091697; PMCID: PMC3945425.
    17. Steele AK, Lee EJ, Manuzak JA, Dillon SM, Beckham JD, McCarter MD, Santiago ML, Wilson CC. Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. Retrovirology. 2014 Feb 04; 11:14. PMID: 24495380; PMCID: PMC3922902.
    18. Manuzak JA, Dillon SM, Lee EJ, Dong ZM, Hecht DK, Wilson CC. Increased Escherichia coli-induced interleukin-23 production by CD16+ monocytes correlates with systemic immune activation in untreated HIV-1-infected individuals. J Virol. 2013 Dec; 87(24):13252-62. PMID: 24067979; PMCID: PMC3838250.
    19. Taiwo B, Matining RM, Zheng L, Lederman MM, Rinaldo CR, Kim PS, Berzins BI, Kuritzkes DR, Jennings A, Eron JJ, Wilson CC. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother. 2013 Aug; 68(8):1857-61. PMID: 23599363; PMCID: PMC3716396.
    20. Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013 Jul 15; 208(2):249-59. PMID: 23559466; PMCID: PMC3685225.
    21. Dillon SM, Manuzak JA, Leone AK, Lee EJ, Rogers LM, McCarter MD, Wilson CC. HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol. 2012 Jul 15; 189(2):885-96. PMID: 22689879; PMCID: PMC3395168.
    22. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011 Nov 13; 25(17):2113-22. PMID: 21857490; PMCID: PMC3515052.
    23. Baumgartner JM, Jordan KR, Hu LJ, Wilson CC, Banerjee A, McCarter MD. DC maturation and function are not altered by melanoma-derived immunosuppressive soluble factors. J Surg Res. 2012 Jul; 176(1):301-8. PMID: 21962733; PMCID: PMC4674430.
    24. Dillon SM, Friedlander LJ, Rogers LM, Meditz AL, Folkvord JM, Connick E, McCarter MD, Wilson CC. Blood myeloid dendritic cells from HIV-1-infected individuals display a proapoptotic profile characterized by decreased Bcl-2 levels and by caspase-3+ frequencies that are associated with levels of plasma viremia and T cell activation in an exploratory study. J Virol. 2011 Jan; 85(1):397-409. PMID: 20962079; PMCID: PMC3014213.
    25. Kassu A, Marcus RA, D'Souza MB, Kelly-McKnight EA, Golden-Mason L, Akkina R, Fontenot AP, Wilson CC, Palmer BE. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol. 2010 Sep 01; 185(5):3007-18. PMID: 20656923; PMCID: PMC3985382.
    26. Dillon SM, Rogers LM, Howe R, Hostetler LA, Buhrman J, McCarter MD, Wilson CC. Human intestinal lamina propria CD1c+ dendritic cells display an activated phenotype at steady state and produce IL-23 in response to TLR7/8 stimulation. J Immunol. 2010 Jun 15; 184(12):6612-21. PMID: 20483758.
      View in: PubMed
    27. Howe R, Dillon S, Rogers L, Palmer B, MaWhinney S, Blyveis N, Schlichtemeier R, D'Souza M, Ingoldby L, Harwood JE, Rietmeijer C, Ray G, Connick E, Wilson CC. Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):444-56. PMID: 19360930.
      View in: PubMed
    28. Howe R, Dillon S, Rogers L, McCarter M, Kelly C, Gonzalez R, Madinger N, Wilson CC. Evidence for dendritic cell-dependent CD4(+) T helper-1 type responses to commensal bacteria in normal human intestinal lamina propria. Clin Immunol. 2009 May; 131(2):317-32. PMID: 19174326; PMCID: PMC2720400.
    29. Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, Palmer BE, Wilson CC, McCarter MD. Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009 Jun 01; 154(1):13-20. PMID: 19062042.
      View in: PubMed
    30. Dillon SM, Robertson KB, Pan SC, Mawhinney S, Meditz AL, Folkvord JM, Connick E, McCarter MD, Wilson CC. Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2008 May 01; 48(1):1-12. PMID: 18300699; PMCID: PMC2529020.
    31. Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley RT, Benson CA. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol. 2008 Jun; 15(6):986-94. PMID: 18400976; PMCID: PMC2446619.
    32. D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, Wilson CC, Connick E, Palmer BE. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol. 2007 Aug 01; 179(3):1979-87. PMID: 17641065.
      View in: PubMed
    33. Boritz E, Rapaport EL, Campbell TB, Koeppe JR, Wilson CC. CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology. 2007 Apr 25; 361(1):34-44. PMID: 17169395.
      View in: PubMed
    34. Barron MA, Blyveis N, Pan SC, Wilson CC. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. J Clin Immunol. 2006 May; 26(3):251-64. PMID: 16783464.
      View in: PubMed
    35. Koeppe JR, Campbell TB, Rapaport EL, Wilson CC. HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr. 2006 Feb 01; 41(2):140-8. PMID: 16394844.
      View in: PubMed
    36. Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol. 2005 Dec 15; 175(12):8415-23. PMID: 16339584.
      View in: PubMed
    37. Fontenot AP, Palmer BE, Sullivan AK, Joslin FG, Wilson CC, Maier LA, Newman LS, Kotzin BL. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J Clin Invest. 2005 Oct; 115(10):2886-93. PMID: 16151531; PMCID: PMC1199530.
    38. Connick E, MaWhinney S, Wilson CC, Campbell TB. Challenges in the study of patients with HIV type 1 seroconversion. Clin Infect Dis. 2005 May 01; 40(9):1355-7. PMID: 15825039.
      View in: PubMed
    39. Boritz E, Palmer BE, Wilson CC. Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol. 2004 Nov; 78(22):12638-46. PMID: 15507650; PMCID: PMC525069.
    40. McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW, Sette A, Essex M, Novitsky V, Newman MJ. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol. 2004 Aug 01; 173(3):1941-50. PMID: 15265928.
      View in: PubMed
    41. Palmer BE, Boritz E, Wilson CC. Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4+ T cell maturation and function. J Immunol. 2004 Mar 01; 172(5):3337-47. PMID: 14978142.
      View in: PubMed
    42. Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol. 2003 Nov 15; 171(10):5611-23. PMID: 14607970.
      View in: PubMed
    43. Boritz E, Palmer BE, Livingston B, Sette A, Wilson CC. Diverse repertoire of HIV-1 p24-specific, IFN-gamma-producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy. J Immunol. 2003 Jan 15; 170(2):1106-16. PMID: 12517980.
      View in: PubMed
    44. Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis. 2003 Jan 01; 187(1):26-37. PMID: 12508143.
      View in: PubMed
    45. Stubbs AC, Wilson CC. Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses. Curr Opin Mol Ther. 2002 Feb; 4(1):35-40. PMID: 11883693.
      View in: PubMed
    Wilson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)